Consensus Statement on Proton Therapy for Prostate Cancer.

IF 2.1 Q3 ONCOLOGY

International Journal of Particle Therapy Pub Date : 2021-04-12 eCollection Date: 2021-01-01 DOI:10.14338/IJPT-20-00031.1

Curtis M Bryant, Randal H Henderson, R Charles Nichols, William M Mendenhall, Bradford S Hoppe, Carlos E Vargas, Thomas B Daniels, C Richard Choo, Rahul R Parikh, Huan Giap, Jerry D Slater, Neha Vapiwala, William Barrett, Akash Nanda, Mark V Mishra, Seungtaek Choi, Jay J Liao, Nancy P Mendenhall

{"title":"Consensus Statement on Proton Therapy for Prostate Cancer.","authors":"Curtis M Bryant, Randal H Henderson, R Charles Nichols, William M Mendenhall, Bradford S Hoppe, Carlos E Vargas, Thomas B Daniels, C Richard Choo, Rahul R Parikh, Huan Giap, Jerry D Slater, Neha Vapiwala, William Barrett, Akash Nanda, Mark V Mishra, Seungtaek Choi, Jay J Liao, Nancy P Mendenhall","doi":"10.14338/IJPT-20-00031.1","DOIUrl":null,"url":null,"abstract":"<p><p>Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective studies have been published documenting the efficacy and safety of proton therapy for patients with localized prostate cancer and for patients requiring adjuvant or salvage pelvic radiation after surgery. The Particle Therapy Co-Operative Group (PTCOG) Genitourinary Subcommittee intends to address current proton therapy indications, advantages, disadvantages, and cost effectiveness. We will also discuss the current landscape of clinical trials. This consensus report can be used to guide clinical practice and research directions.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 2","pages":"1-16"},"PeriodicalIF":2.1000,"publicationDate":"2021-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489490/pdf/","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Particle Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14338/IJPT-20-00031.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective studies have been published documenting the efficacy and safety of proton therapy for patients with localized prostate cancer and for patients requiring adjuvant or salvage pelvic radiation after surgery. The Particle Therapy Co-Operative Group (PTCOG) Genitourinary Subcommittee intends to address current proton therapy indications, advantages, disadvantages, and cost effectiveness. We will also discuss the current landscape of clinical trials. This consensus report can be used to guide clinical practice and research directions.

Abstract Image

查看原文本刊更多论文

前列腺癌质子治疗的共识声明。

质子治疗是治疗癌症的一种有前景但有争议的治疗方法。尽管与光子放射疗法相比，它具有剂量测量优势，但它增加了患者和保险公司的成本，这引发了人们对其价值的质疑。已经发表了多项前瞻性和回顾性研究，记录了质子治疗对局限性前列腺癌症患者和术后需要辅助或挽救性骨盆放射的患者的有效性和安全性。粒子治疗合作小组（PTCOG）泌尿生殖小组委员会旨在解决当前质子治疗的适应症、优点、缺点和成本效益。我们还将讨论临床试验的现状。这份共识报告可用于指导临床实践和研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊